Figure 5
![Figure 5. Structure of eltrombopag. Eltrombopag [3′-{N′-[1-(3,4-Dimethyl-phenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2′-hydroxybiphenyl-3-carboxylic acid] has an acidic (COOH) group at one end, lipophilic (CH3) groups at the other end, and a metal chelate group in the center, which create a potent, orally available TPO nonpeptide agonist. Illustration by Paulette Dennis.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/109/11/10.1182_blood-2006-10-019315/4/zh80110703760005.jpeg?Expires=1735824442&Signature=mW3NDOvWuB139lbyhBhYKHsk0S2huymngl1g8BwzsPSJOxlHCJ5XhYKnaiGNttD9~jljOE5exchpa9QFKLh5~qwQHHMBKgOHewnMPHqXs2AVMDCfoyqNkLlDxj~pvr6KkZYbMo4ZP~g4F4EGa16A0YwLvsQXHxVQx1kfnIC4rNK2f4cwuTGpVBNAlgGN6bdA4YoiAEb9JDDlMVBShUQgL4zB5zljYX~fPp62z60nSZLze3IW70CTegEO9uw8FRhub4CFw0iQfSJ8QDmj~wvgPQ4FmtppO1mMg0idrZg-hybs1ePKz3Ph0aPnR-n2-WuB7VIWjY32b1Ngvsb~X9Ynng__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Structure of eltrombopag. Eltrombopag [3′-{N′-[1-(3,4-Dimethyl-phenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2′-hydroxybiphenyl-3-carboxylic acid] has an acidic (COOH) group at one end, lipophilic (CH3) groups at the other end, and a metal chelate group in the center, which create a potent, orally available TPO nonpeptide agonist. Illustration by Paulette Dennis.
